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different BDMARD, disenrollment from health insurance, reaching March 31, 
2011 or follow-up of 36 months. Exposure periods were subdivided into a 
quarterly (90-day) repeated-measures panel dataset. Within each quarter-panel, 
OGC use and rituximab adherence, measured using the proportion of days 
covered (PDC), were measured. Multivariable generalized estimating equation 
models examined the association between quarterly OGC use and prior quarter 
(lagged) PDC, adjusting for confounding variables. Multivariable-adjusted OGC 
use probabilities were predicted by PDC level (PDC=0 [i.e., reinfusion≥90 days 
late]; PDC=50 [reinfusion=45 days late]; PDC≥100 [reinfusion=on time/early]) 
using the G-computation method. RESULTS: Sample comprised 4,583 quarter-
panels (594 unique patients); mean age 55 years, 81% female. The multivariable-
adjusted OGC use probabilities decreased with time (p<0.001) and increasing PDC 
(p=0.006): from approximately 0.72 for all PDC levels in the first quarter-panel to 
0.64 (PDC=0), 0.55 (PDC=50), and 0.47 (PDC≥100) in the last (12th) quarter-panel. 
CONCLUSIONS: Increasing rituximab adherence was associated with statistically 
significant OGC use reduction over time.  
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OBJECTIVES: To estimate the adherence to oral bisphosphonate medication use 
and its associated factors for patients with osteoporosis in Tianjin, China. 
METHODS: Data were obtained from the Tianjin Urban Employee Basic Medical 
Insurance (UEBMI) database (2008-2010) with 30% random selection. Patients 
with ≥ 1 osteoporosis diagnosis, aged 40 years and older, and who had ≥ 1 
pharmacy claim for oral bisphosphonate, including alendronate and etidronate, 
were selected. 12-month continuous enrollment before and after the first 
pharmacy claim for oral bisphosphonate were required. Adherence was 
measured with a medication possession ratio (MPR) and accounted for 6-month 
and 12-month. Multivariate logistic regression (MLR) analysis was conducted to 
assess the odds ratios (ORs) with 95% confidence intervals (CI) of potential 
confounding factors. RESULTS: A total of 918 patients with osteoporosis were 
identified with 64.9% female and a mean age of 64.7 (±10.4) years. The mean MPR 
was 0.24 (±0.25) and 0.13 (±0.15) at 6-month and 12-month follow-up period 
respectively. 96.62% of patients with MPR <50% and 81.05% of patients with MPR 
<20% were found in the 12-month analyses compared with 87.25% and 62.42% in 
the 6-month analysis respectively. During the first 6-month period, 48.69% of 
patients had only one bisphosphonate pharmacy claim and decreased to 47.82% 
when followed to 12-month. MLR results showed that patients with prior 
fractures during the study period may have better compliance (OR=3.15 and 
CI=1.23-8.10) while patients with coronary disease may have poorer compliance 
(OR=0.18 and CI=0.69-0.48) after adjusting for patients demographic and 
comorbidity characteristics. CONCLUSIONS: The adherence of oral 
bisphosphonate therapy for osteoporosis patients in Tianjin was significantly 
poorer compared to previous research in developed countries. More attentions 
should be paid and policy guidance is needed to improve the medication 
adherence among patients with osteoporosis in China.  
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OBJECTIVES: To examine the differential impact of a physical versus a mental 
co-morbid condition on the health state utility (HSU) of patients with an existing 
physical condition. METHODS: Four base physical (B-Phys) conditions were 
examined: arthritis, asthma, diabetes and migraine. For each B-Phys, 5 physical 
co-morbidities (Co-Phys) were selected based on published clinical and 
epidemiologic studies; depression and anxiety were selected as the 2 mental co-
morbidities (Co-Mental). Mean HSUs (and 95% confidence intervals) were 
calculated for patients with only B-Phys and for patients with the B-Phys and 
either a Co-Phys or a Co-Mental. Data came from individuals (N=26,885) with one 
or two of the selected conditions who participated in the National Health and 
Wellness Study between 2007 and 2010. HSUs, calculated based on the SF-6D, 
were age- and gender-adjusted to reflect the mean age and gender composition 
of the sample. RESULTS: Patients with a Co-Phys had lower HSUs (mean 
differences ranged from -0.018 for asthma, to -0.061 for diabetes) when 
compared to patients with only B-Phys. However, these differences were 
substantially greater for subjects with a Co-Mental instead of a Co-Phys (mean 
differences ranged from -0.081 for asthma, to -0.093 for arthritis). The mean 
difference between the HSUs of patients with only the B-Phys and those of 
patients with both B-Phys and Co-Mental were between 1.4 (Diabetes) and 4.5 
(Asthma) times higher than the difference between patients with B-Phys and B-
Phys and Co-Phys. CONCLUSIONS: Economic evaluations of interventions are 
often based on published utilities among patients with a specific condition 
regardless of their other co-morbidities. Our results suggest that having a Co-
Mental has a substantially greater impact on HSUs than a Co-Phys. Studies 
aimed at evaluating interventions among patients with a particular condition 
must take into account the prevalence and type of co-morbidities among the 
population of interest.  
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OBJECTIVES: Physical function(PF) is an important determinant of health in the 
osteoarthritis (OA) population. Patient reported outcomes(PRO) are often used as 
primary endpoints for clinical research yet PROs measure attributes of PF that 
differ from performance-based measures [i.e., walking speed(WS)]. WS has been 
proposed as the “ sixth vital sign,” and a powerful predictor of health status and 
functional decline. The purpose of this study was to determine whether WS 
differs between community-dwelling African-American (AA) and White 
American (WA) adults with OA symptoms. METHODS: Participants were 1371 
individuals (27% African American) from the Osteoarthritis Initiative, a 
prospective observational cohort. Included individuals had both 1) ≥ 1 pain, 
aching, or stiffness in or around the knee on most days for at least 1 month 
during the past 12 months, and 2) the presence of osteophytes-grade 1. Linear 
regression models examined racial differences in WS adjusting for age, gender, 
education, body mass index (BMI), income, education, waist circumference, and 
comorbidities. RESULTS: WS was significantly slower for AA than WA, (mean 
speed 1.15m/s vs. 1.31m/s; p<0.001). Compared to the WA cohort, the AA cohort 
had more females (71% vs. 51%; p<0.001), were younger [mean age(SD) 60.0(8.5) 
vs. 61.9 (9.3); p<0.001], had a higher mean BMI [32.4(5.0)kg/m2 vs. 29.4(4.7) kg/m2; 
p<0.001], and lower income and education level. AAs had higher (p<0.001) 
prevalence of hypertension (18% vs. 10%), diabetes (23% vs. 7%), and rheumatoid 
arthritis (9.9% vs. 1.1%). Racial differences in WS persisted when controlling for 
age, gender, education, body mass index (BMI), income, education, waist 
circumference, and comorbidities (excluding RA). CONCLUSIONS: In this study, 
race is an independent predictor of WS. Establishing National Norms for WS by 
race and gender should be investigated before using WS as a health status 
measure and health outcome predictor.  
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OBJECTIVES: Quality of life (QoL) is increasingly being included as a secondary 
endpoint in clinical trials, with reimbursement agencies requesting information 
on the wider impact of an intervention on the patient. The quality-adjusted life 
years (QALYs) used in cost-utility analyses take their weighting of life years 
gained with an intervention from the QoL scores calculated using utility 
instruments such as the EQ-5D. The question that this poses is, what precisely 
are such utility instruments measuring, and is this a good reflection of the 
improvements in health that society wishes to finance? The aim of this study 
was to use the case study of rheumatoid arthritis (RA) to demonstrate the extent 
to which clinical trials add to our understanding of the psycho-social QoL 
outcomes of an intervention, as opposed to pain and physical function. 
METHODS: All completed phase III/IV trials in RA with results listed on 
ClinicalTrials.gov were assessed for QoL outcomes and utility instrument used. 
The relative proportion of each instrument accounting for ‘psycho-social’ versus 
‘pain and physical function’, as defined by the SF-36 dimensions, was compared. 
RESULTS: Of the 76 studies analysed, 20 measured QoL (16 using SF-36, 2 using 
EQ-5D, 4 using both). The percentage of variance in each instrument attributable 
to pain and physical function versus psycho-social outcomes, as defined by SF-
36 dimensions, was applied to these results (EQ-5D: 88.8%=Pain and physical 
function, 11.2%=Psycho-social; SF-6D: 70.5%=Pain and physical function, 
29.5%=Psycho-social). It was found that only 24.5% of the QoL results available 
report on the psychosocial implications of the intervention. CONCLUSIONS: In 
conclusion, only a very small proportion of trials in this chronic condition 
measure the QoL outcomes of their interventions, and breaking down utility 
instruments into their component dimensions shows that only a small 
proportion of the total QoL outcomes reflect psycho-social implications.  
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OBJECTIVES: Empirical comparison of two preference elicitation methods, 
discrete choice experiment (DCE) and profile case best-worst scaling (BWS), 
regarding the estimation of the risk tolerance for hip replacement surgery (total 
hip arthroplasty and total hip resurfacing arthroplasty). METHODS: An online 
survey was constructed, following international guidelines, and consisted of 
socio-demographic questions and two randomised sections with 12 DCE and 8 
BWS questions. The survey was sent to a general population who can be faced 
with choosing between THA and TRA (males between 45-65 years old) in the US. 
After an intensive literature search, the following attributes were selected: 
probability of a first and a second revision in seven years, pain relief, ability to 
perform moderate daily activities, and hospital stay. In addition, survey 
respondents rated the difficulty of each method and the time to complete each 
section was monitored. BWS and DCE data was analysed using conditional logit 
analysis. The maximum acceptable risk (MAR) for a revision was estimated for 
four different hypothetical hip replacement scenarios. RESULTS: The final data 
set consisted of 429 respondents. The MARs estimated for four hypothetical hip 
replacement scenarios differed between both methods, ranging from 0% to 19% 
difference for a first revision. BWS questions took significantly more time (401 s.) 
than DCE (228 s.) questions. And respondents found BWS more difficult to 
complete. CONCLUSIONS: Both methods to elicit stakeholder preferences 
produce different results. Yet, both seem to be consistent in predicting risk 
